Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Si Yang

Showing results (821-830 of 839) with videos related to

Pageof 84
Sort By:
Clinical Lung Cancer|October 25, 2023
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)Jia-Tao Zhang, Song Dong, Wei-Quan Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Antimicrobial Agents and Chemotherapy|May 24, 2022
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis TreatmentEric L Nuermberger, Maria Santos Martínez-Martínez, Olalla Sanz, et al.
Acta Neuropathologica Communications|September 17, 2024
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumorsRichard A Hickman, Alexandra M Miller, Bridget M Holle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2026
LAMPAD:An Integrated ctDNA-Based Model for Predicting Potential Cure in Resected NSCLC PatientsJia-Tao Zhang, Ke-Zhong Chen, Xuan Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2024
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancerSi-Yang Liu, Tatiana Erazo, Justin Jee, et al.
Cell Reports|August 8, 2024
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLCYang-Si Li, Wen-Pu Lai, Kai Yin, et al.
Nature Medicine|July 24, 2023
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSi-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastasesYang-Si Li, Wenpu Lai, Kai Yin, et al.
NPJ Vaccines|February 29, 2024
Immune persistence after different polio sequential immunization schedules in Chinese infantsTing Zhao, Jing Li, Teng Huang, et al.
Pageof 84

Showing results (821-830 of 839) with videos related to

Sort By:
Pageof 84
Clinical Lung Cancer|October 25, 2023
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)Jia-Tao Zhang, Song Dong, Wei-Quan Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Antimicrobial Agents and Chemotherapy|May 24, 2022
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis TreatmentEric L Nuermberger, Maria Santos Martínez-Martínez, Olalla Sanz, et al.
Acta Neuropathologica Communications|September 17, 2024
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumorsRichard A Hickman, Alexandra M Miller, Bridget M Holle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2026
LAMPAD:An Integrated ctDNA-Based Model for Predicting Potential Cure in Resected NSCLC PatientsJia-Tao Zhang, Ke-Zhong Chen, Xuan Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2024
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancerSi-Yang Liu, Tatiana Erazo, Justin Jee, et al.
Cell Reports|August 8, 2024
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLCYang-Si Li, Wen-Pu Lai, Kai Yin, et al.
Nature Medicine|July 24, 2023
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSi-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastasesYang-Si Li, Wenpu Lai, Kai Yin, et al.
NPJ Vaccines|February 29, 2024
Immune persistence after different polio sequential immunization schedules in Chinese infantsTing Zhao, Jing Li, Teng Huang, et al.
Pageof 84